Cervical cancer often develops gradually, progressing from precancerous lesions influenced by persistent HPV infection and immune system dysregulation. While Pap smears and HPV tests are important tools, they may not capture the earliest molecular immune responses that precede cancer development.

The Cervical Immunocarcinogenic Assay provides a biomarker-based evaluation of immune activity and tumor-promoting inflammation associated with cervical carcinogenesis. This test offers clinicians and patients a more complete picture of risk, aiding early detection, treatment decisions, and long-term monitoring.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Cervical Immunocarcinogenic Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Beyond HPV Testing

Detects immune activity and molecular disruptions beyond viral screening.

Early Warning

Identifies immune and inflammatory changes that signal heightened risk of cervical cancer.

Personalized Care

Supports decisions for surveillance, treatment, and prevention strategies.

Monitoring Capability

Tracks immune-molecular changes over time in high-risk or post-treatment patients.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Cervical Immunocarcinogenic Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and HPV-driven carcinogenesis:

  • Immune checkpoint proteins (PD-L1, CTLA-4 pathways)

  • Pro-inflammatory cytokines (IL-6, IL-8, TNF-α)

  • Tumor microenvironment markers linked to HPV-driven carcinogenesis

  • Angiogenesis signals (VEGF, FGF)

  • Cellular stress and metabolic imbalance indicators

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Patient registers through Persona Biomed’s secure portal.

02

Sample Collection

Blood draw at a certified clinic or via mobile phlebotomy.

03

Laboratory Analysis

High-sensitivity assays evaluate immune and prometastatic activity specific to cervical cancer pathways.

04

Results Delivery

Clinical interpretation report accessible in the patient portal, including physician-ready details and AI-friendly patient summaries.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Patients with persistent HPV infection or abnormal Pap smear results.

  • Women with a family history of cervical cancer.

  • Individuals undergoing treatment or surveillance for cervical dysplasia or carcinoma.

  • High-risk populations in regions with limited access to advanced screening.

Register Now for
Cervical Immunocarcinogenic Assay

Register now for the Cervical Immunocarcinogenic Assay to detect immune-driven cervical cancer risks early and guide precision prevention and treatment.

Register now